Publications

January 1994 (Revised July 1998)
Case

Repligen Corporation: January 1992

By: Josh Lerner and David Kane

Sandford Smith, CEO of Repligen, faces the breakdown of negotiations about a proposed joint venture with a large pharmaceutical firm. He must decide whether to proceed using his firm's internal resources or whether to seek to revise the proposed collaboration. If the... View Details

Keywords: Joint Ventures; Decisions; Contracts; Agreements and Arrangements; Value

January 1994 (Revised November 2001)
Background Note

Note on the Venture Leasing Industry, A

Provides an overview of venture leasing, an innovative financing mechanism that resembles both venture equity investments and bank lending. View Details

Keywords: Finance

January 1994 (Revised April 1995)
Case

EMC Corporation: Response to Shareholder Litigation (A)

EMC Corp. is the target of a shareholder class-action lawsuit for the second time. CEO, Richard Egan, must decide whether to settle the case, as is done in 96% of such cases and as EMC itself did previously, or fight the action. View Details

Keywords: Decision Choices and Conditions; Lawsuits and Litigation; Going Public; Management Teams; Business and Shareholder Relations; Technology Industry; United States

January 1994 (Revised April 1994)
Case

EMC Corporation: Response to Shareholder Litigation (B)

Reports EMC's decision concerning the second shareholder class-action suit and its implications. Legislative efforts to reform securities litigation are also discussed. View Details

Keywords: Decisions; Lawsuits and Litigation; Going Public; Policy; Management Teams; Business and Shareholder Relations; Technology Industry; United States

April 1993 (Revised October 1995)
Case

ALZA and Bio-Electro Systems (A): Technological and Financial Innovation

To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details

Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Medical Devices and Supplies Industry

April 1993 (Revised February 1996)
Supplement

ALZA and Bio-Electro Systems (B1): Rights Offering Strategy

Supplements the (A) case. Describes the CEO's decision. View Details

Keywords: Strategy; Intellectual Property

April 1993 (Revised February 1996)
Supplement

ALZA and Bio-Electro Systems (B2): The Rights Offering

Supplements the (A) case. Describes the implementation of the CEO's decision. View Details

Keywords: Intellectual Property

April 1993 (Revised February 1996)
Supplement

ALZA and Bio-Electro Systems (C): 1988-92

Supplements the (A) case. Describes the aftermarket performance of the units. View Details

Keywords: Performance

March 1993 (Revised May 1998)
Teaching Note

ImmuLogic Pharmaceutical Corporation (Series) TN

Teaching Note for (9-293-066--071) and (9-293-087). View Details

Keywords: Pharmaceutical Industry

1993
Article

Innovation and the Structure of High-Technology Industries

Keywords: Innovation and Invention; Information Technology; Business Ventures

Find at Harvard

December 1992 (Revised September 1996)
Case

ImmuLogic Pharmaceutical Corporation (Abridged)

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details

Keywords: Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Pharmaceutical Industry; United States

October 1992 (Revised November 1997)
Case

ImmuLogic Pharmaceutical Corporation (A): March 1991

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details

Keywords: Decisions; Entrepreneurship; Venture Capital; Banks and Banking; Initial Public Offering; Going Public; Perspective; Valuation; Biotechnology Industry; Pharmaceutical Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised April 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B2): Henry McCance

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised April 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

October 1992 (Revised March 1993)
Supplement

ImmuLogic Pharmaceutical Corporation (C): April 1991

Supplements the (A) case. View Details

Keywords: Pharmaceutical Industry

Teaching Interest

Owner/President Management Progam (Executive Education)

As business owners and entrepreneurs prepare to take their companies to the next level in a highly competitive global arena, they must be fully equipped to master a range of skills—from strategy development to financial management to team... View Details

Teaching Interest

Private Equity and Venture Capital (Executive Education)